תוצאות חיפוש - Satlin, Andrew

Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease מאת Satlin, Andrew, Wang, Jinping, Logovinsky, Veronika, Berry, Scott, Swanson, Chad, Dhadda, Shobha, Berry, Donald A.

קבל טקסט מלא קבל טקסט מלא קבל טקסט מלא

S221. THE EFFICACY OF LUMATEPERONE 42 MG IN THE TREATMENT OF SCHIZOPHRENIA SYMPTOMS ASSOCIATED WITH SOCIAL FUNCTIONING: POST HOC ANALYSIS OF AN ACUTE PLACEBO- AND ACTIVE-CONTROLLED... מאת Vanover, Kimberly, Davis, Robert, Durgam, Suresh, Huo, Jason, Mates, Sharon, Satlin, Andrew, Harvey, Philip D

קבל טקסט מלא קבל טקסט מלא

T205. LUMATEPERONE IN THE TREATMENT OF SCHIZOPHRENIA: EVALUATION OF EXTRAPYRAMIDAL AND MOTOR SYMPTOMS IN 4 LATE-PHASE CLINICAL TRIALS מאת Durgam, Suresh, Satlin, Andrew, Davis, Robert E, Vanover, Kimberly E, Mates, Sharon, Kane, John M

קבל טקסט מלא קבל טקסט מלא

Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease מאת Lannfelt, Lars, Möller, Christer, Basun, Hans, Osswald, Gunilla, Sehlin, Dag, Satlin, Andrew, Logovinsky, Veronika, Gellerfors, Pär

קבל טקסט מלא קבל טקסט מלא קבל טקסט מלא

Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody מאת Logovinsky, Veronika, Satlin, Andrew, Lai, Robert, Swanson, Chad, Kaplow, June, Osswald, Gunilla, Basun, Hans, Lannfelt, Lars

קבל טקסט מלא קבל טקסט מלא קבל טקסט מלא

M205. LONG-TERM SAFETY OF LUMATEPERONE (ITI-007): METABOLIC EFFECTS IN A 1-YEAR STUDY מאת Satlin, Andrew, Durgam, Suresh, Vanover, Kimberly E, Davis, Robert E, Huo, Jason, Mates, Sharon, Correll, Christoph

קבל טקסט מלא קבל טקסט מלא

Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials מאת Kane, John M, Durgam, Suresh, Satlin, Andrew, Vanover, Kimberly E, Chen, Richard, Davis, Robert, Mates, Sharon

קבל טקסט מלא קבל טקסט מלא קבל טקסט מלא

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease מאת Farlow, Martin, Veloso, Felix, Moline, Margaret, Yardley, Jane, Brand-Schieber, Elimor, Bibbiani, Francesco, Zou, Heng, Hsu, Timothy, Satlin, Andrew

קבל טקסט מלא קבל טקסט מלא קבל טקסט מלא

Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study מאת Murphy, Patricia, Moline, Margaret, Mayleben, David, Rosenberg, Russell, Zammit, Gary, Pinner, Kate, Dhadda, Shobha, Hong, Quan, Giorgi, Luigi, Satlin, Andrew

קבל טקסט מלא קבל טקסט מלא קבל טקסט מלא

F46. LUMATEPERONE (ITI-007): FAVORABLE SAFETY PROFILE IN AN OPEN LABEL SAFETY SWITCHING STUDY FROM STANDARD-OF-CARE ANTIPSYCHOTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA מאת Davis, Robert, Dmitrienko, Alex, Glass, Steven, Kozauer, Susan, Saillard, Jelena, Weingart, Michal, Satlin, Andrew, Mates, Sharon, Correll, Christoph, Vanover, Kimberly

קבל טקסט מלא קבל טקסט מלא

S44. LUMATEPERONE (ITI-007) FOR THE TREATMENT OF SCHIZOPHRENIA: PLACEBO-CONTROLLED CLINICAL TRIALS AND AN OPEN-LABEL SAFETY SWITCHING STUDY מאת Vanover, Kimberly, Dmitrienko, Alex, Glass, Steven, Kozauer, Susan, Saillard, Jelena, Weingart, Michal, Satlin, Andrew, Mates, Sharon, Correll, Christoph, Davis, Robert

קבל טקסט מלא קבל טקסט מלא

Dorsomedial SCN neuronal subpopulations subserve different functions in human dementia מאת Harper, David G., Stopa, Edward G., Kuo-Leblanc, Victoria, McKee, Ann C., Asayama, Kentaro, Volicer, Ladislav, Kowall, Neil, Satlin, Andrew

קבל טקסט מלא קבל טקסט מלא קבל טקסט מלא

S117. FAVORABLE LONG-TERM SAFETY PROFILE OF LUMATEPERONE IITI-007): RESULTS FROM A 12 MONTH OPEN LABEL SAFETY STUDY FOR LUMATEPERONE IN PATIENTS WITH STABLE SYMPTOMS OF SCHIZOPHREN... מאת Vanover, Kimberly, Satlin, Andrew, Durgam, Saresh, Weingart, Michal, Saillard, Jelena, Sanchez, Juan, Hossain, Shawon, Glass, Steven, Kozauer, Susan, Mates, Sharon, Davis, Robert

קבל טקסט מלא קבל טקסט מלא

Effectiveness and Tolerability of High-Dose (23 mg/d) Versus Standard-Dose (10 mg/d) Donepezil in Moderate to Severe Alzheimer’s Disease: A 24-Week, Randomized, Double-Blind Study... מאת Farlow, Martin R., Salloway, Stephen, Tariot, Pierre N., Yardley, Jane, Moline, Margaret L., Wang, Qin, Brand-Schieber, Elimor, Zou, Heng, Hsu, Timothy, Satlin, Andrew

קבל טקסט מלא קבל טקסט מלא קבל טקסט מלא

ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials מאת Wang, Jinping, Logovinsky, Veronika, Hendrix, Suzanne B, Stanworth, Stephanie H, Perdomo, Carlos, Xu, Lu, Dhadda, Shobha, Do, Ira, Rabe, Martin, Luthman, Johan, Cummings, Jeffrey, Satlin, Andrew

קבל טקסט מלא קבל טקסט מלא קבל טקסט מלא

Acute Hemodynamic Effects and Tolerability of Phosphodiesterase 1-Inhibition with ITI-214 in Human Systolic Heart Failure: Gilotra, Phosphodiesterase-1 inhibition in heart failure מאת Gilotra, Nisha A., DeVore, Adam D., Povsic, Thomas J., Hays, Allison G., Hahn, Virginia S., Agunbiade, Tolu A., DeLong, Allison, Satlin, Andrew, Chen, Richard, Davis, Robert, Kass, David A.

קבל טקסט מלא קבל טקסט מלא קבל טקסט מלא

Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms מאת Lanctôt, Krista L., Amatniek, Joan, Ancoli-Israel, Sonia, Arnold, Steven E., Ballard, Clive, Cohen-Mansfield, Jiska, Ismail, Zahinoor, Lyketsos, Constantine, Miller, David S., Musiek, Erik, Osorio, Ricardo S., Rosenberg, Paul B., Satlin, Andrew, Steffens, David, Tariot, Pierre, Bain, Lisa J., Carrillo, Maria C., Hendrix, James A., Jurgens, Heidi, Boot, Brendon

קבל טקסט מלא קבל טקסט מלא קבל טקסט מלא